Arnold L Eugene, Young Andrea S, Belury Martha A, Cole Rachel M, Gracious Barbara, Seidenfeld Adina M, Wolfson Hannah, Fristad Mary A
1 Department of Psychiatry and Behavioral Health, The Ohio State University , Columbus, Ohio.
2 Department of Psychiatry, Johns Hopkins University , Baltimore, Maryland.
J Child Adolesc Psychopharmacol. 2017 Apr;27(3):223-233. doi: 10.1089/cap.2016.0123. Epub 2017 Feb 3.
To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders.
In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23.
At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: the greater the EPA increase, the less the placebo-controlled Ω3 improvement.
Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.
研究青少年情绪障碍患者的脂肪酸谱、ω-3脂肪酸(Ω3)补充剂对其的影响,以及脂肪酸谱与临床状态和治疗反应之间的关联。
在一项安慰剂对照的2×2设计中,7至14岁的儿童(N = 95)参与平行先导试验(抑郁症患者N = 72;双相情感障碍患者N = 23),被随机分配接受12周的Ω3补充剂治疗(每天1.4克二十碳五烯酸[EPA]、0.2克二十二碳六烯酸[DHA]和0.27克其他Ω3);心理教育心理治疗(PEP);两者联合治疗;或仅接受安慰剂治疗(主要为油酸和亚油酸)。在基线期(N = 90)和终点期(n = 65)采集血液样本。脂肪酸水平以总血浆脂肪酸的百分比表示。使用SPSS Statistics 23进行相关性分析以及调节/中介分析。
在基线期:(1)DHA与α-亚麻酸(ALA)呈负相关(r = -0.23,p = 0.029);(2)花生四烯酸(AA,Ω6)与整体功能呈负相关(r = -0.24,p = 0.022);(3)总Ω3与年龄(r = -0.22,p = 0.036)和舒张压(r = -0.31,p = 0.006)呈负相关。调节作用:基线期的ALA调节了对Ω3补充剂的反应:ALA水平高于样本均值(DHA水平较低)预示着安慰剂对照反应显著更好(p = 0.04)。补充剂效果:与安慰剂相比,每天2克Ω3使EPA血液水平提高了7倍,DHA水平提高了一半(均p < 0.001)。体重与EPA增加量(r = -0.52,p = 0.004)和DHA增加量(r = -0.54,p = 0.003)呈负相关,与临床情绪反应呈正相关。中介作用:EPA从基线到终点的增加介导了安慰剂对照的整体功能改善和抑郁症状改善:EPA增加量越大,安慰剂对照的Ω3改善效果越小。
每天补充2克Ω3可显著提高血液水平,对年龄较小的儿童效果更明显。应探索可能的U型反应曲线。